Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 3
2011 2
2013 2
2014 4
2017 2
2018 2
2019 2
2020 2
2021 1
2022 2
2023 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
[Kidney disease care for the elderly].
Hamroun A, Frimat M, Beuscart JB, Buob D, Lionet A, Lebas C, Daroux M, Provôt F, Hazzan M, Boulanger É, Glowacki F. Hamroun A, et al. Among authors: daroux m. Nephrol Ther. 2019 Dec;15(7):533-552. doi: 10.1016/j.nephro.2019.10.001. Epub 2019 Nov 9. Nephrol Ther. 2019. PMID: 31711751 Review. French.
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
Rossignol P, Zannad F, Massy Z, Azizi M, Chorfa F, Coadic J, Ferreira JP, Saraiva F, Mottier D, Guillemin F, Ngueyon Sime W, Bouali S, Rossignol B, Nortier J, Simon I, Robino C, Davin M, Bataille PM, Chantrel F, Castin N, Esnault V, Kazes I, Hannedouche T, Kamar N, Achard JM, Fenerol C, Achard-Hottelart C, Dimitrov Y, Girerd N, Maucourt-Boulch D, Frimat L; ALCHEMIST study group. Rossignol P, et al. Lancet. 2025 Aug 16;406(10504):705-718. doi: 10.1016/S0140-6736(25)01194-8. Lancet. 2025. PMID: 40818851 Clinical Trial.
Early Renal Recovery after the First Flare of Pauci-Immune Glomerulonephritis.
Zaworski J, Gnemmi V, Bataille P, Hachulla E, Glowacki F, Gibier JB, Daroux M, Ratsimbazafy A, Bitton L, Humez S, Guincestre T, Béhal H, Azar R, Hoffmann M, Cardon G, Bourdon F, Lemoine C, Auxenfant E, Copin MC, Vandenbussche C, Quéméneur T; pour la cohorte RENVAS. Zaworski J, et al. Among authors: daroux m. Am J Nephrol. 2022;53(1):59-68. doi: 10.1159/000520285. Epub 2022 Jan 17. Am J Nephrol. 2022. PMID: 35038711
[Cognitive impairment and chronic kidney disease: which links?].
Gaxatte C, Daroux M, Bloch J, Puisieux F, Deramecourt V, Boulanger E. Gaxatte C, et al. Among authors: daroux m. Nephrol Ther. 2011 Feb;7(1):10-7. doi: 10.1016/j.nephro.2010.09.001. Epub 2010 Nov 2. Nephrol Ther. 2011. PMID: 21050832 Review. French.
24 results